MariMed is a multi-state cannabis company focused on the development, ownership and operation of regulated facilities for medical and adult-use cannabis markets, with operations encompassing cultivation, formulation, manufacturing and retail. The company recently strengthened its financial position through debt restructuring to enhance liquidity and strategic flexibility.
Cyborg Score Rationale
The company reported negative net margin of 11.36% and negative return on equity of 14.67%, indicating profitability challenges. However, the recent debt restructuring reduces near-term refinancing risk and enhances liquidity profile, providing some operational breathing room.
Top Insights
Series B preferred stock obligation of $14.725 million extended through 2031, removing immediate 2026 conversion pressure
Trailing twelve-month revenue of $157M as of September 2025
Portfolio includes five award-winning cannabis brands recognized and loved by consumers across the country
Debt-to-equity ratio of 1.34 with quick ratio of 0.35, indicating elevated leverage and potential liquidity constraints
Named Competitors
Cannabis cultivation and retail — Multi-state cannabis operator
Cannabis consumer products — Multi-state cannabis company
Cannabis operations — Multi-state operator
Recent Developments
(March 2026) Extends Series B Preferred Stock obligation through 2031, improving capital structure
(March 2026) Fourth Quarter 2025 earnings announcement scheduled for March 11
(February 2026) Betty's Eddies introduces new Limited-Edition Valentine's seasonal product
Open the full interactive MariMed Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.